These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 27169615)

  • 41. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.
    Terao T; Yuda J; Yamauchi N; Guo YM; Shimada K; Sugano M; Ishii G; Minami Y
    Mol Clin Oncol; 2021 Jun; 14(6):125. PubMed ID: 33936598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Durable Responses with Brentuximab Vedotin in cHL.
    Cancer Discov; 2016 Sep; 6(9):OF1. PubMed ID: 27507410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
    Pierce JM; Mehta A
    Expert Rev Hematol; 2017 Jan; 10(1):29-37. PubMed ID: 27927047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
    Nikolaenko L; Nademanee A
    Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.
    Mallipudi RM; Alquran L; Shenoy VA; Leslie LA; Conti JA
    Case Rep Oncol Med; 2019; 2019():4121234. PubMed ID: 31110830
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis.
    Sano D; Liu N; Knowles S; MacEwan JP; Wang S; Wogen J; Yu KS; Lee ST
    Curr Oncol; 2024 May; 31(5):2598-2609. PubMed ID: 38785476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
    Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
    Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
    Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
    Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas.
    Malysz J; Erdman P; Klapper J; Zhu J; Creer M; Bayerl MG
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):429-33. PubMed ID: 27521276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
    Pham A; Chen R
    Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma.
    Thiruvengadam SK; Mei MG; Chen L; Puverel S; Chen R; Popplewell LL; Nikolaenko L; Peters L; Armenian S; Kwak LW; Rosen ST; Forman SJ; Herrera AF
    Clin Lymphoma Myeloma Leuk; 2024 Oct; 24(10):724-731.e1. PubMed ID: 39043499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
    van der Weyden CA; Pileri SA; Feldman AL; Whisstock J; Prince HM
    Blood Cancer J; 2017 Sep; 7(9):e603. PubMed ID: 28885612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin.
    Lobastova L; Lettau M; Babatz F; de Oliveira TD; Nguyen PH; Pauletti BA; Schauss AC; Dürkop H; Janssen O; Paes Leme AF; Hallek M; Hansen HP
    Front Cell Dev Biol; 2021; 9():698503. PubMed ID: 34395429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
    Rinaldi I
    Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.
    Salihoglu A; Elverdi T; Karadogan I; Paydas S; Ozdemir E; Erdem G; Karadurmus N; Akyol G; Kaynar L; Yegin Z; Sucak G; Ozkocaman V; Topcuoglu P; Ozcan M; Birtas E; Goker H; Baslar Z; Ferhanoglu B
    Ann Hematol; 2015 Mar; 94(3):415-20. PubMed ID: 25231929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.